Bluebird Bio (BLUE) Receives a Buy from Cowen & Co.

Cowen & Co. analyst Yaron Werber maintained a Buy rating on Bluebird Bio (BLUEResearch Report) today. The company’s shares closed last Monday at $80.24, close to its 52-week low of $71.42.

According to, Werber is a 5-star analyst with an average return of 16.5% and a 68.4% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Springworks Therapeutics, and Rocket Pharmaceuticals.

Currently, the analyst consensus on Bluebird Bio is a Moderate Buy with an average price target of $105.71, representing a 30.3% upside. In a report issued on November 26, Leerink Partners also upgraded the stock to Buy with a $119.00 price target.

See today’s analyst top recommended stocks >>

Based on Bluebird Bio’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $206 million. In comparison, last year the company had a GAAP net loss of $145 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.